StockData
iBio, Inc. logo

iBio, Inc. (IBIO) company profile

IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/30
$0.75+0.04 (+5.86%)

Close on Nov 17, 2026Market cap $48.11MP/E –Yield –

About iBio

Pharmaceutical Preparations, SIC 2834

iBio, Inc. is a clinical-stage biotechnology company that develops precision antibody therapeutics for obesity, cardiometabolic conditions, and cardiopulmonary diseases. Operating through an integrated artificial intelligence and machine learning drug discovery platform, the company designs biologic candidates directed against complex, hard-to-drug targets. Its pipeline includes IBIO-600, an anti-myostatin antibody in clinical development, alongside preclinical candidates such as IBIO-610, an Activin E antibody, and IBIO-800, a bispecific antibody for cardiopulmonary indications. Additionally, the company develops T-cell engaging bispecific antibodies for oncology and collaborates with partners such as AstralBio on engineered amylin receptor agonist antibodies.

The company conducts research and development activities at its laboratory facility in San Diego, California. Clinical development for its lead candidate has extended internationally, with clinical trial activity and participant enrollment initiated in Australia. The text does not disclose the location of corporate headquarters, total facilities, or commercial customer segments.

Summary of the business section of iBio's latest annual report, written by StockData.

Company profile

Company

Legal name
iBio, Inc.
Headquarters
New York, NY
Address
600 Madison Avenue, Suite 1601 10022-1737
Phone
(302) 355-0650
Employees
23, Jun 30, 2026
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
June 30
Auditor
GRASSI & Co., CPAs, P.C., Jericho, New York

Stock & identifiers

Ticker
IBIO
Exchange
Nasdaq
IPO date
Aug 19, 2008
Shares outstanding
64M, Aug 27, 2026
Public float
$57.51M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-20 reverse, Nov 29, 2023; 1-for-25 reverse, Oct 10, 2022; 1-for-10 reverse, Jun 11, 2018
SEC CIK
1420720
CUSIP
451033708
ISIN
US4510337086
FIGI
BBG000D5F2L9
Share class FIGI
BBG001T0R8W3
LEI
529900EW4RXUITGKUT34
EIN
26-2797813

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Martin BrennerSee Remarks, Director30,652
Molly CarrChief Medical Officer–
Marc BanjakChief Legal Officer25,000
Felipe DuranChief Financial Officer35,974
Gary SenderDirector9,191
Alexandra KropotovaDirector–
William D. ClarkDirector1,838
David ArkowitzDirector18,382
Elizabeth StonerDirector–
Antonio Bernardino Guimaraes ParadaDirector183,823
Evert B. SchimmelpenninkDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2026$2.14M$2.31M$1.02M$14–
FY2025$1.51M$621.72K$741.49K$6–
FY2024$1.27M$1.18M$761.87K$17–
FY2023
Current Chief Executive Officer Martin Brenner
$1.07M$629.45K$630.74K$9–
FY2023
Former Chief Executive Officer Thomas Isett
$1.67M$189.27K$630.74K$9–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2026

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Dr. Martin B. Brenner
Chief Executive Officer and Chief Scientific Officer
$580.00K$1.22M$319.00K$13.68K$2.14M+42%
Felipe Duran
Chief Financial Officer
$415.50K$464.37K$182.82K$18.61K$1.08M+40%
Marc Banjak
Chief Legal Officer
$400.00K$373.28K$176.00K$17.18K$966.46K+36%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of August 27, 2026, we had 23 employees, all of which are full-time employees, in addition to two strategic consultants.”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 1, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 3, 2025ListingRegistration of securities on an exchange (Form 8-A)
Mar 3, 2025DelistingNotice of delisting from exchange (Form 25)
Feb 19, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 5, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 26, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 21, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 16, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 29, 2022Late filingNotification of late filing
Sep 21, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 4, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 28, 2020Late filingNotification of late filing
Jan 16, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 13, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 22, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 26, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 22, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 8, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 5, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 14, 2017Late filingNotification of late filing
Nov 14, 2016Late filingNotification of late filing
Sep 28, 2016Late filingNotification of late filing
May 16, 2016Late filingNotification of late filing
Feb 17, 2016Late filingNotification of late filing
Sep 28, 2015Late filingNotification of late filing
Feb 17, 2015Late filingNotification of late filing
Jun 5, 2013Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 16, 2013Late filingNotification of late filing
Apr 22, 2013Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 4, 2013Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)

See a number that looks wrong?